Migraine – Drug Pipeline Analysis and Market Forecasts to 2016

Migraine Market Has Declined Since 2008 and This Decline is Forecast to Continue to 2016

Online PR News – 23-January-2010 – – GlobalData estimated the global migraine market to be worth $3.9 billion in 2009. It is forecast to decrease at a compound annual growth rate (CAGR) of 2.7% over the next seven years to reach $3.2 billion by 2016. This decrease in the growth rate can be primarily attributed to the increased competition among the existing products, the patent expirations of standard triptans, the availability of prophylactic drugs, the accessibility of cheaper pain relievers, a weak pipeline with limited drugs and high levels of patient satisfaction with generic and me-too drugs. The migraine market has passed its mature phase and entered into its declining phase in terms of revenue. However, the migraine market will see static growth in the next seven years. Until 2008, GlaxoSmithKline plc (GSK) led the migraine market with its blockbuster drug Imitrex. On August 6, 2008, Imitrex has lost its patent exclusivity, which decreased its sales from $1 billion to less than $200m in 2009.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Migraine-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015

GlobalData has found that GlaxoSmithKline plc. (GSK), Eli Lilly And Company, Merck & Co., Inc., Pozen, Inc., Eisai Co., Ltd., Johnson & Johnson Services, Inc., NuPathe Inc., Abbott Laboratories are the leading competitors in the global migraine market. Together, these companies accounted for more than 40% of the global migraine market in 2009. The rest of the market was held by generic versions and prophylactic migraine drugs that include beta blockers, calcium channel blockers, anti-depressants and anticonvulsants. After the patent expiry of GSK’s Imitrex in mid 2008, the migraine market declined sharply. Until the end of 2007, Imitrex was the market leader, generating revenues worth more than $1.5 billion. GSK had three approved drugs in the migraine market until the end of 2008. Due to the expiry of these three drugs’ patents, GSK’s revenues in the migraine market will decline until its pipeline drugs are launched. GSK has many drugs in its migraine pipeline with either new mechanisms of action or that are similar to me-toos.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Migraine-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015

GlobalData, the industry analysis specialist, has released its latest research, “Migraine – Drug Pipeline Analysis and Market Forecasts to 2016” that provides key data, information and analysis on the migraine market. The report provides a comprehensive overview on the annualized market data from 2006 to 2009, forecast forward to seven years till 2016. Report directs towards various concepts that relates to migraine market. Data in the report is incorporated with compilation of primary research and secondary research. Concepts included in the report are market characterization, opportunities and unmet needs associated with migraine drugs, competitive assessment, product profiles of major marketed products and promising drugs from pipeline, an overview on the discontinued projects, tables for migraine pipeline drugs that are in various development stages, pipeline by therapeutic class, implications for future market competition, key future players for migraine market.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Migraine-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015

Or Visit our report store: http://www.globaldata.com/reportstore

Bookmarkse-mailGoogledel.icio.usStumbleUponSlashdotFurlDiggTechnoratiYahooMyWebBlinkListSpurlRawSugarWists
 
 
Contact Information
Rajesh Gunnam
Progressive House, Maidstone Road, Foots Cray, Sidcup
Kent London, DA14 5HZ

+914066166782